Affiliation:
1. BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE
2. «MOTHER AND CHILD» MEDICAL CENTER, KYIV, UKRAINE
Abstract
The aim: Our aim was to assess the hemostatic potential of patients with liver cirrhosis and atrial fibrillation by LPTEG global coagulation assay, to investigate changes in LPTEG parameters
according to the stage of liver cirrhosis and compare results with liver cirrhosis group.
Materials and methods: We performed a prospective cross-sectional study including 70 patients with liver cirrhosis and atrial fibrillation, 36 patients with liver cirrhosis and
20 healthy individuals. LPTEG parameters were measured using ARP-01M “Mednord” in order to assess coagulation abnormalities.
Results: t1 and Intensity of contact coagulation didn't differ (p>0,05), Constant of thrombin activity was increased (47.53±0.8vs.34.51±1.88, p<0.001), t3 was reduced
(5,0±0.1vs.6.7±0.36 p<0.001), Intensity of coagulation drive was increased (52.8±1.8vs.38.55±1.54, p = 0.001), Intensity of clot polymerization was increased (19.66±0.28vs.16.29±0.28,
p<0.001), time t5 was reduced (32.94±0.36 vs. 36.8±1.30, p<0.01), Maximum amplitude was increased (655.7±9.19 vs. 547±19.38, p<0.001), Intensity of total coagulation
was increased (19.41±0.34vs.15,09±0.56, p<0.001), Intensity of clot retraction and lysis was increased (4.1±0.07vs.3±0.15, p<0.001) and Coefficient of total anticoagulant
activity was increased (2.81±0.05 vs. 2.48 ± 0.06, p<0.001) compared to liver cirrhosis.
Conclusions: In patients with liver cirrhosis and atrial fibrillation the hemostatic potential is significantly shifted towards hypercoagulation with a gradual worsening of
coagulation disorders, starting from the compensated stage of liver cirrhosis.
Reference22 articles.
1. 1. Roth G.A., Abate D., Abate K.H. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet. 2018;392(10159):1736-1788
2. 2. Asrani S.K., Devarbhavi H. Burden of liver diseases in the world. J Hepatol. 2019; 70(1):151-171.
3. 3. Sarin S.K., Maiwall R. Global Burden Of Liver Disease: A True Burden on Health Sciences and Economies. World Gastroenterology Organisation. https://www.worldgastroenterology.org/publications/e-wgn/e-wgnexpert-point-of-view-articles-collection/global-burden-of-liverdisease-a-true-burden-on-health-sciences-and-economies.
4. 4. Munger T.M., Wu L.Q., Shen W.K. Atrial Fibrillation. JBR. 2014; 28(1):1-17.
5. 5. Chung M.K., Eckhardt L.L., Chen L.Y. et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement from the American Heart Association. Circulation. 2020; 141 (16): 750-772.